Ontology highlight
ABSTRACT: Importance
This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC).Objective
To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC.Design, setting, and participants
This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020.Interventions
Patients were ra
SUBMITTER: Wang J
PROVIDER: S-EPMC8017481 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature